Table 1.
Patient demographics
| Pre‐HU, n = 14 | On HU at MTD, n = 11 | P value | |
|---|---|---|---|
| Age (years) | 11.0 ± 3.2 | ||
| Gender | 86% Male | ||
| HU dose (g/dL) | 16.5 ± 4.3 | ||
| WBC (× 109/L) | 9.2 ± 3.2 | 5.8 ± 2.1 | 0.004 |
| Hb (g/dL) | 11.4 ± 1.3 | 11.2 ± 1.2 | NS |
| MCV (fL) | 69.7 ± 4.4 | 85.8 ± 8.1 | <0.001 |
| MCHC (g/dL) | 36.4 ± 1.0 | 36.2 ± 0.87 | NS |
| Platelet count (× 109/L) | 225 ± 76 | 167 ± 80 | NS |
| ANC (× 106/L) | 4685 ± 2190 | 2304 ± 933 | 0.002 |
| ARC (× 109/L) | 150 ± 60 | 107 ± 30 | NS |
| %HbF | 1.7 ± 1.9 | 6.3 ± 6.7 | 0.02 |
HU, hydroxyurea; MTD, maximum tolerated dose. Pre‐HU values are laboratory values immediately preceding initiation of hydroxyurea. On‐HU at MTD values are laboratory values at least six months after initiating hydroxyurea, at MTD as defined in the text.